News Release

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

Kyowa Hakko Kirin News Releases 2012

December 25, 2012
Completion of Construction of a New Facility for Formulation of Solid Dosage Forms at the Ube Plant
December 19, 2012
Announcement Regarding Applications for Approval of Pediatric Indication and Additional Formulation of Topina®, an Antiepileptic Agent
December 13, 2012
Kyowa Hakko Kirin Initiates Pivotal Phase 3 Trial of Mogamulizumab (KW-0761) in Patients with Cutaneous T-Cell Lymphoma in the United States
December 11, 2012
Results of a Phase 2 Clinical Trial on Mogamulizumab (KW-0761) to Treat Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL) in Japan
December 3, 2012
Long-Acting Erythropoiesis Stimulating Agent NESP® INJECTION PLASTIC SYRINGE with Unified Injection Volume Released for Sale
November 21, 2012
Kyowa Hakko Kirin Submits Application for Additional Indication of Pheochromocytoma for Dacarbazine Injection 100
November 13, 2012
Announcement regarding the Filing in Japan of an Application for Marketing Approval of KW-2246 for Cancer Pain Treatment
October 30, 2012
Kyowa Hakko Kirin Announces Discontinuation for Phase 3 Clinical Study of ARQ 197 (Tivantinib) in Combination with Erlotinib in Non-Small-Cell Lung Cancer PatientsPDF file:New window opens(20KB)
October 26, 2012
Kyowa Hakko Kirin Announces Q3 resultsPDF file:New window opens(184KB)
October 26, 2012
Consolidated Financial Summary Fiscal 2012, Third QuarterPDF file:New window opens(232KB)
October 26, 2012
Appendix to the Fiscal 2012 Third Quarter Consolidated Financial StatementsPDF file:New window opens(96KB)
October 26, 2012
Kyowa Hakko Bio Announces Establishment of a Subsidiary and a New Amino Acid Manufacturing Plant in Thailand
October 24, 2012
Fujifilm Kyowa Kirin Biologics to initiate development of biosimilar of bevacizumab, an anti-VEGF humanized monoclonal antibody which has impressive therapeutic effects for cancers such as colorectal cancer
October 19, 2012
Construction work commenced for the biopharmaceutical API manufacturing facility in the Takasaki Plant
October 19, 2012
Kyowa Hakko Kirin Announces Suspension of Early Phase 2 Clinical Study of Bardoxolone methyl (RTA 402) in Patients with Chronic Kidney Disease and Type 2 Diabetes in JapanPDF file:New window opens(14KB)
October 4, 2012
Application Seeking Approval for Additional Indications for Intramuscular Administration and Dosage of Leunase® Injection 5000 KU and Leunase® Injection 10000 KU
October 1, 2012
New window opensProStrakan Acquires Breast Cancer Product for the USPDF file:New window opens(90KB)
October 1, 2012
Launch of Kyowa Hakko Kirin Global Website
September 28, 2012
Application for time-window extension of the thrombolytic agents GRTPA® and ACTIVACIN® up to 4.5 hours after the onset of symptoms of ischemic cerebrovascular diseasePDF file:New window opens(20KB)
September 26, 2012
Conversion of Kyowa Hakko Kirin Korea Co., Ltd. into wholly owned subsidiary
September 14, 2012
Kyowa Hakko Kirin returns to Otsuka Pharmaceutical the rights to develop and market Busulfex®, for use as a part of conditioning regimen prior to hematopoietic progenitor cell transplantation, in Japan and in Asian Countries & Regions
August 31, 2012
Pasetocin® and Sawacillin®: Joint Application Seeking Approval for Additional Indication for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitors and either Clarithromycin or Metronidazole
August 30, 2012
Kyowa Hakko Kirin Announces Temporary Suspension of Patient Enrollment for Phase 3 Clinical Study of ARQ 197 (Tivantinib) in Combination with Erlotinib in Non-Small-Cell Lung Cancer PatientsPDF file:New window opens(12KB)
August 23, 2012
Kyowa Hakko Kirin Initiates Pivotal Phase 2 Trial of Mogamulizumab (KW-0761) in Patients with Adult T-cell Leukemia-Lymphoma in the United States and Europe
July 27, 2012
Kyowa Hakko Kirin Announces First Half Results for Fiscal 2012PDF file:New window opens(40KB)
July 27, 2012
Consolidated Financial Summary Fiscal 2012 InterimPDF file:New window opens(208KB)
July 27, 2012
Appendix to the Fiscal 2012 Interim Consolidated Financial StatementsPDF file:New window opens(264KB)
July 27, 2012
FY December 2012 Interim Results MeetingPDF file:New window opens(1206KB)
July 26, 2012
Launch of Apokyn® Subcutaneous Injection 30 mg for Treatment of Parkinson's Disease
July 19, 2012
Kyowa Hakko Kirin Revises ForecastsPDF file:New window opens(56KB)
June 29, 2012
Otsuka Pharmaceutical and Kyowa Hakko Kirin announce strategic alliance in the fields of diabetes and oncology
May 29, 2012
Launch of POTELIGEO® (Mogamulizumab) Injection in Japan,
a Therapeutic Antibody for Adult T-cell Leukemia-Lymphoma (ATL)
May 29, 2012
Launch and Co-Promotion of "MINIRINMELT® OD Tablet 120μg / 240μg", A Treatment of Nocturnal Enuresis / Bedwetting
May 25, 2012
Change in the Company Name of JEIL-KIRIN PHARMACEUTICAL INC.
May 7, 2012
Kyowa Medex Launched POTELIGEO® TEST IHC and POTELIGEO® TEST FCM,Companion Diagnostics of POTELIGEO® Injection in Japan
April 26, 2012
Kyowa Hakko Kirin Announces Q1 resultsPDF file:New window opens(48KB)
April 26, 2012
Consolidated Financial Summary First Quarter of the Fiscal Year to December 2012PDF file:New window opens(180KB)
April 26, 2012
Appendix to the Fiscal 2012 First Quarter Consolidated Financial StatementsPDF file:New window opens(216KB)
April 26, 2012
Change of the Name of Kirin Kunpeng (China) Bio-Pharmaceutical Co., Ltd.
April 26, 2012
Notice regarding allotment of stock acquisition rights(stock compensation-type stock options)PDF file:New window opens(80KB)
April 2, 2012
Announcement regarding the Filing in Japan of
an Application for Marketing Approval of KW-6002 for
Parkinson's Disease Treatment
March 30, 2012
New Drug Application Approval for
POTELIGEO® (Mogamulizumab) Injection in Japan,
a Therapeutic Antibody for Adult T-cell Leukemia-Lymphoma (ATL)
March 30, 2012
Kyowa Medex Receives Approval for
POTELIGEO® TEST IHC and POTELIGEO® TEST FCM,
Companion Diagnostics of POTELIGEO® Injection in Japan
March 30, 2012
Announcement regarding Marketing Authorization Approval in Japan of Apokyn® Subcutaneous Injection 30 mg (Apomorphine Hydrochloride Hydrate) for Treatment of Parkinson's Disease
March 30, 2012
Matters concerning controlling shareholdersPDF file:New window opens(56KB)
March 27, 2012
Establishment of Fujifilm Kyowa Kirin Biologics
-Joint-Venture of Fujifilm and Kyowa Hakko Kirin for the development, manufacturing and sales of biosimilars-
February 24, 2012
Notice regarding completion and status of repurchase of own sharesPDF file:New window opens(48KB)
February 22, 2012
Position and policies concerning the reduction of the minimum investment unitPDF file:New window opens(40KB)
February 22, 2012
Notice regarding stock acquisition rights for the purpose of granting stock compensation-type stock optionsPDF file:New window opens(100KB)
February 1, 2012
Notice regarding status of repurchase of own sharesPDF file:New window opens(48KB)
January 31, 2012
Kyowa Hakko Kirin Fiscal 2011 Results: Record operating income and ordinary incomePDF file:New window opens(84KB)
January 31, 2012
Consolidated Financial Summary Fiscal 2011PDF file:New window opens(568KB)
January 31, 2012
Appendix to the Fiscal 2011 Consolidated Financial StatementsPDF file:New window opens(136KB)
January 31, 2012
Kyowa Hakko Kirin Fiscal 2011 Results (Fiscal year to December 31, 2011)PDF file:New window opens(760KB)
January 31, 2012
Kyowa Hakko Kirin Announces Change of Representative DirectorsPDF file:New window opens(36KB)
January 31, 2012
Withdrawal of domestic application for the additional "chemotherapy-induced anemia" indication for NESPPDF file:New window opens(16KB)
January 6, 2012
Notice regarding status of repurchase of own sharesPDF file:New window opens(48KB)

Get Adobe® Reader®You need Adobe® Reader® to view these documents.
Download Adobe® Reader® of Adobe Systems here.



To Page Top